

Consumer Sector - FMCG

2QFY24 Result Preview

October 7, 2023

Muted topline and volume growth persists

Key Points

- Early commentaries from some of the FMCG players like Marico, Dabur and Godrej Consumer Products suggest that the overall demand environment remains muted.
- On rural demand, we believe that the overall recovery is not that sharp and is not broad-based across categories.
- 2QFY24 will witness significant YoY gross margin expansion for several companies but rising ad spends (off a low base), significantly lower realization growth vs preceding quarters and persistently tepid volume growth mean that YoY growth at EBITDA margin level will not be material for most players. As highlighted in our [commodity cost note](#) released recently, some raw material prices (especially food related) remain elevated and crude oil has also witnessed a spurt recently.
- We are expecting our FMCG coverage universe to clock revenue growth of 5.2% YoY.

Steady demand environment: Early commentaries from a few FMCG players like Marico, Dabur and Godrej Consumer Products suggest that the overall demand environment remains muted with some signs of a gradual recovery. On rural demand, we believe that the overall recovery, although not sharp, is witnessing some signs of slow revival. Marico indicated that the anticipated pick-up in rural demand was hindered due to an upward trend in food prices and below-normal distribution of rainfall. In terms of categories, while Beverages segment revenue is likely to decline on account of a mild summer and delayed festive season, Home Care category is expected to witness some positive momentum. Dabur India, Tata Consumer's (TCPL) India Foods business and Nestle India are expected to deliver relatively better 4-year volume CAGR.

Expect mid single-digit revenue growth: We are expecting our FMCG coverage universe to clock revenue growth of 5.2% YoY, which is muted because of significantly lower realization growth vs preceding quarters along with persistently tepid volume growth. We expect gross margin for most of our coverage companies to improve on YoY basis. As highlighted in our recently released [input cost note](#), while prices of key commodities like Brent Crude/Malaysian Palm Oil have seen ~13%/~4% YoY correction in 2QFY24, commodities like Wheat and Milk have seen ~5%/8% YoY rise in prices. For the overall FMCG coverage, we expect EBITDA margin to expand by ~110bps YoY.

What to watch out for in 2QFY24: We expect HMN to deliver relatively better EBITDA growth on YoY basis. **Preference on 1-year forward basis:** GILL and BRIT.

Key monitorables: (1) Effect of late monsoon recovery on rural income and the consequent impact on rural demand (2) Impact of festive season on off-takes.

Please refer to the disclaimer towards the end of the document.

Company (Rsmn)	Revenue			EBITDA			EBITDA margin (%)			PAT		
	2QFY24E	YoY(%)	QoQ(%)	2QFY24E	YoY(%)	QoQ(%)	2QFY24E	2QFY23	1QFY24	2QFY24E	YoY(%)	QoQ(%)
Britannia	45,986	5.0	14.7	7,864	10.5	14.2	17.1	16.3	17.2	5,442	10.3	18.9
Colgate-Palmolive	15,198	9.5	14.8	4,708	15.4	12.6	31.0	29.4	31.6	3,278	17.9	13.8
Dabur India	32,397	8.5	3.5	6,544	8.9	8.2	20.2	20.1	19.3	5,004	2.1	7.9
Emami	8,827	8.5	6.9	2,560	31.0	34.7	29.0	24.0	23.0	2,231	7.5	38.7
Gillette India **	6,826	10.1	10.2	1,392	2.6	-3.1	20.4	21.9	23.2	884	1.9	-3.6
Hindustan Unilever	1,51,935	3.0	0.3	34,945	3.5	-0.8	23.0	22.9	23.2	25,000	5.1	0.0
ITC	1,67,924	4.1	6.1	64,651	10.2	3.4	38.5	36.4	39.5	50,137	12.3	2.3
Marico	24,514	-1.8	-1.0	4,976	14.9	-13.3	20.3	17.3	23.2	3,448	14.6	-19.2
Nestle India **	50,850	10.5	9.2	11,720	16.0	10.7	23.0	21.9	22.7	7,891	18.2	12.5
Tata Consumer	37,262	10.8	-0.4	5,478	26.3	0.5	14.7	12.9	14.6	3,480	6.1	9.9
PGHH**	11,471	10.0	34.6	2,580	20.6	20.1	22.5	20.5	25.2	1,868	21.0	23.5
Coverage universe	5,53,190	5.2	5.1	1,47,419	10.1	3.7	26.6	25.5	27.0	1,08,663	10.3	3.9

Source: Company; Nirmal Bang Institutional Equities Research; **1QFY24 for Gillette India, PGHH and 3QCY23 for Nestle India

Exhibit 1: Expect moderate volume growth

Vol./SSG growth (%)	2Q20	3Q20	4Q20	1Q21	2Q21	3Q21	4Q21	1Q22	2Q22	3Q22	4Q22	1Q23	2Q23	3Q23	4Q23	1Q24	2Q24E	v. 2Q20*
Britannia (Base business)	3.0	3.0	0.0	21.5	9.0	4.0	8.0	1.0	2.0	6.0	4.5	-2.0	5.0	2.0	2.0	0.0	3.0	4.7
Colgate (Toothpaste)*	4.0	2.3	-8.0	-2.0	4.0	5.0	16.5	6.0	4.0	2.0	-3.0	-2.0	-1.0	-3.0	-2.0	6.0	5.0	3.0
Dabur (Domestic FMCG)	4.8	5.6	-14.6	-9.7	16.8	18.1	25.4	34.4	10.0	2.0	2.0	5.0	1.0	-3.0	0.0	3.0	4.0	7.8
Emami (Domestic)	0.0	-2.0	-20.0	-28.0	10.0	13.0	39.0	38.0	5.5	0.0	0.0	0.0	-1.2	-3.9	2.0	3.0	5.0	4.7
HUL (Domestic)* ²	5.0	5.0	-7.0	-8.0	1.0	4.0	16.0	9.0	4.0	2.0	0.0	6.0	4.0	5.0	4.0	3.0	3.0	3.0
ITC (Cigarette)*	3.0	2.0	-12.0	-37.0	-12.0	-7.5	7.0	30.0	9.0	13.0	9.0	26.0	20.0	15.0	12.0	8.0	-2.0	3.1
Marico (Domestic)	1.0	-1.0	-3.0	-14.0	11.0	15.0	25.0	21.0	8.0	0.0	1.0	-6.0	3.0	4.0	5.0	3.0	3.0	6.2
Nestle (Domestic)	6.2	4.8	5.5	-11.2	6.7	10.0	10.3	25.2	6.3	5.0	7.8	7.0	8.8	-0.8	5.1	5.1	7.0	7.2
TCPL (India Beverages)	8.0	7.0	5.0	4.0	11.0	10.0	23.0	3.0	2.0	6.0	3.0	1.0	-1.0	-5.0	3.0	3.0	3.0	3.7
TCPL (India Foods)	-	-	-1.0	8.0	6.0	12.0	21.0	17.0	16.0	4.0	-1.0	-3.0	0.0	4.0	8.0	6.0	8.0	7.3

Source: Company; Nirmal Bang Institutional Equities Research

*Our estimates; *2 HUL standalone domestic volume excluding Nutrition; # 4-yr CAGR basis (Indexed to 2QFY20)

BRIT: We expect BRIT's base business volume to grow in low single digit in 2QFY24 (4-yr CAGR: ~5%) with a volume-led topline growth of 5% YoY. Gross margin is expected to improve by ~360bps YoY (up 60bps QoQ), leading to EBITDA margin expansion of ~80bps YoY to 17.1% (down 10bps QoQ). EBITDA and APAT are estimated to grow by 10.5% YoY and 10.3% YoY, respectively.

CLGT: We expect CLGT to deliver revenue growth of 9.5% YoY as we estimate Toothpaste volume growth to be in mid single digit YoY (4-yr CAGR: 3%). We expect operating margin to expand by ~160bps YoY to 31%, albeit on a low base. EBITDA is expected to increase by 15.4% YoY and APAT is likely to increase by 17.9% YoY.

DABUR: We expect Dabur to deliver 4% YoY domestic FMCG volume growth (4-yr CAGR: 7.8%) and ~8.5% YoY revenue growth at the consolidated level. As per the company, both Healthcare and HPC businesses are projected to achieve high single-digit growth while the F&B business is likely to witness marginally lower growth on YoY basis on account of a mild summer and change in the timing of the festive season. EBITDA margin is likely to stay flat YoY at 20.2% (up ~90bps QoQ). EBITDA is expected to increase by 8.9% YoY and APAT by 2.1% YoY.

EMAMI: We expect the company's domestic volume to grow in mid single digit, leading to an overall revenue growth of 8.5% YoY. Operating margin is expected to improve by ~500bps YoY to 29% on a low base. EBITDA is expected to increase by 31% YoY whereas APAT (before amortization) is likely to improve by 7.5% YoY.

GILL: We expect GILL to post revenue growth of 10.1% YoY in 1QFY24 (June-ending fiscal year). We expect EBITDA margin to decline by ~150bps YoY to ~20.4% (down 280bps QoQ). Absolute EBITDA and APAT are expected to increase by 2.6% YoY and 1.9% YoY, respectively.

HUL: We expect HUL to post moderate volume growth of 3% YoY (4-yr CAGR: 3%), driving 3% YoY revenue growth (including the Nutrition business). Revenue growth is largely reflecting volume growth as we expect no material benefit from realisations. We expect gross margin to significantly expand by 440bps YoY, but on a QoQ basis it is likely to see a modest rise of 30bps as there has been no material moderation in Net Material Inflation (NMI). While gross margin expansion is likely to be strong on YoY basis, no material increase in EBITDA margin is expected due to lower sales growth and higher ad spends, resulting in flat EBITDA margin on both QoQ as well as YoY basis at 23%. EBITDA and APAT are likely to grow by 3.5% YoY and 5.1% YoY, respectively.

ITC: We expect ITC's overall topline to be muted at ~4% YoY due to likely decline on Paperboards, Paper & Packaging segment owing to lower pulp prices and relatively lower Cigarette segment sales growth on a high base. Cigarette sales are likely to grow by a muted rate of 3% YoY due to volume decline of 2% YoY. But, volume growth on a 4-yr CAGR basis is likely to remain healthy at 3.1%. We expect the growth momentum in Other-FMCG business to continue, with ~10% YoY growth in the segment. Further, we expect the Hotels business to grow by 10% YoY and the Agri business to grow by 12% YoY on a high base. But, Paperboards, Paper & Packaging business is expected to decline by 3% YoY. At the company level, we expect EBITDA margin to expand by ~210bps YoY to 38.5% (down 100bps QoQ) on the back of improved profitability in Other-FMCG segment and Agri business segment on YoY basis. EBITDA and APAT are likely to grow by 10.2% YoY and 12.3% YoY, respectively.

MRCO: We expect MRCO's consolidated revenue to decline by 1.8% YoY [with low single-digit volume growth in the Domestic business (4-yr CAGR: 6.2%)], as price cuts taken in the Edible Oils portfolio will weigh on the overall growth, along with negative impact of currency depreciation in some overseas markets. Gross margin is expected to expand by ~490bps YoY (down 150bps QoQ). We expect EBITDA margin to expand by ~300bps YoY (down 290bps QoQ). EBITDA and APAT are likely to grow by 14.9% YoY and 14.6% YoY, respectively.

NEST: NEST is likely to post a topline growth of 10.5% YoY with 7% YoY volume growth (4-yr CAGR: 7.2%) in 3QCY23. Gross margin is likely to expand by ~230bps YoY (flat QoQ). We expect EBITDA margin to expand by ~110bps YoY to 23% (+30bps QoQ). EBITDA and APAT are likely to grow by 16% YoY and 18.2% YoY, respectively.

TCPL: We expect TCPL to clock 10.8% YoY revenue growth. Volume will likely see improvement at the company level. We expect volume growth to be in low single-digits for India Beverages and high single-digits for India Foods businesses (4-yr CAGR: 3.7% and 7.3%, respectively). We expect gross margin to expand by 80bps on YoY basis (+30bps QoQ). EBITDA margin is likely to come in at 14.7% (up 180bps YoY and flat QoQ). EBITDA is likely to grow by 26.3% YoY and APAT by 6.1% YoY.

PGHH: We expect PGHH to post revenue growth of 10% YoY in 1QFY24 (June-ending fiscal year). We expect EBITDA margin to expand by ~200bps YoY to 22.5% (down 270bps QoQ). Absolute EBITDA and APAT are expected to increase by 20.6% YoY and 21% YoY, respectively.

DISCLOSURES

This Report is published by Nirmal Bang Equities Private Limited (hereinafter referred to as “NBEPL”) for private circulation. NBEPL is a registered Research Analyst under SEBI (Research Analyst) Regulations, 2014 having Registration no. INH000001436. NBEPL is also a registered Stock Broker with National Stock Exchange of India Limited and BSE Limited in cash and derivatives segments.

NBEPL has other business divisions with independent research teams separated by Chinese walls, and therefore may, at times, have different or contrary views on stocks and markets.

NBEPL or its associates have not been debarred / suspended by SEBI or any other regulatory authority for accessing / dealing in securities Market. NBEPL, its associates or analyst or his relatives do not hold any financial interest in the subject company. NBEPL or its associates or Analyst do not have any conflict or material conflict of interest at the time of publication of the research report with the subject company. NBEPL or its associates or Analyst or his relatives do not hold beneficial ownership of 1% or more in the subject company at the end of the month immediately preceding the date of publication of this research report.

NBEPL or its associates / analyst has not received any compensation / managed or co-managed public offering of securities of the company covered by Analyst during the past twelve months. NBEPL or its associates have not received any compensation or other benefits from the company covered by Analyst or third party in connection with the research report. Analyst has not served as an officer, director or employee of Subject Company and NBEPL / analyst has not been engaged in market making activity of the subject company.

Analyst Certification: I/We, Krishnan Sambamoorthy, Research Analyst and Sunny Bhadra, Research Associate, the author(s) of this report, hereby certify that the views expressed in this research report accurately reflects my/our personal views about the subject securities, issuers, products, sectors or industries. It is also certified that no part of the compensation of the analyst was, is, or will be directly or indirectly related to the inclusion of specific recommendations or views in this research. The analyst is principally responsible for the preparation of this research report and has taken reasonable care to achieve and maintain independence and objectivity in making any recommendations.

Disclaimer

Stock Ratings Absolute Returns

BUY > 15%

ACCUMULATE -5% to 15%

SELL < -5%

This report is for the personal information of the authorized recipient and does not construe to be any investment, legal or taxation advice to you. NBEPL is not soliciting any action based upon it. Nothing in this research shall be construed as a solicitation to buy or sell any security or product, or to engage in or refrain from engaging in any such transaction. In preparing this research, we did not take into account the investment objectives, financial situation and particular needs of the reader.

This research has been prepared for the general use of the clients of NBEPL and must not be copied, either in whole or in part, or distributed or redistributed to any other person in any form. If you are not the intended recipient you must not use or disclose the information in this research in any way. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. NBEPL will not treat recipients as customers by virtue of their receiving this report. This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject NBEPL & its group companies to registration or licensing requirements within such jurisdictions.

The report is based on the information obtained from sources believed to be reliable, but we do not make any representation or warranty that it is accurate, complete or up-to-date and it should not be relied upon as such. We accept no obligation to correct or update the information or opinions in it. NBEPL or any of its affiliates or employees shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. NBEPL or any of its affiliates or employees do not provide, at any time, any express or implied warranty of any kind, regarding any matter pertaining to this report, including without limitation the implied warranties of merchantability, fitness for a particular purpose, and non-infringement. The recipients of this report should rely on their own investigations.

This information is subject to change without any prior notice. NBEPL reserves its absolute discretion and right to make or refrain from making modifications and alterations to this statement from time to time. Nevertheless, NBEPL is committed to providing independent and transparent recommendations to its clients, and would be happy to provide information in response to specific client queries.

Before making an investment decision on the basis of this research, the reader needs to consider, with or without the assistance of an adviser, whether the advice is appropriate in light of their particular investment needs, objectives and financial circumstances. There are risks involved in securities trading. The price of securities can and does fluctuate, and an individual security may even become valueless. International investors are reminded of the additional risks inherent in international investments, such as currency fluctuations and international stock market or economic conditions, which may adversely affect the value of the investment. Opinions expressed are subject to change without any notice. Neither the company nor the director or the employees of NBEPL accept any liability whatsoever for any direct, indirect, consequential or other loss arising from any use of this research and/or further communication in relation to this research. Here it may be noted that neither NBEPL, nor its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profit that may arise from or in connection with the use of the information contained in this report.

Copyright of this document vests exclusively with NBEPL.

Our reports are also available on our website www.nirmalbang.com

Access all our reports on Bloomberg, Thomson Reuters and Factset.

Team Details:			
Name		Email Id	Direct Line
Rahul Arora	CEO	rahul.arora@nirmalbang.com	-
Krishnan Sambamoorthy	Head of Research	krishnan.s@nirmalbang.com	+91 22 6273 8210
Dealing			
Ravi Jagtiani	Dealing Desk	ravi.jagtiani@nirmalbang.com	+91 22 6273 8230, +91 22 6636 8833
Michael Pillai	Dealing Desk	michael.pillai@nirmalbang.com	+91 22 6273 8102/8103, +91 22 6636 8830

Nirmal Bang Equities Pvt. Ltd.

Correspondence Address

B-2, 301/302, Marathon Innova,
Nr. Peninsula Corporate Park,
Lower Parel (W), Mumbai-400013.
Board No. : 91 22 6273 8000/1; Fax. : 022 6273 8010